Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

1 May 2003

Abstract excerpt

Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the protein determined by immunohistochemistry (IHC) are the two major methods to establish this status. A strong correlation has been previously demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12771927
DOI: 10.1038/sj.bjc.6600943

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerPMID 12771927Read ↗

Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaSemantic proximity Read ↗

Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancerSemantic proximity Read ↗

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring studySemantic proximity Read ↗

Emerging Technologies for Assessing HER2 AmplificationSemantic proximity Read ↗

Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridizationSemantic proximity Read ↗

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)Semantic proximity Read ↗

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ HybridizationSemantic proximity Read ↗

Determination of <i>HER2</i> amplification in primary breast cancer using dual‐colour chromogenic <i>in situ</i> hybridization is comparable to fluorescence <i>in situ</i> hybridization: a European multicentre study involving 168 specimensSemantic proximity Read ↗

Interlaboratory Comparison of<b><i>HER-2</i></b>Oncogene Amplification as Detected by Chromogenic and Fluorescence<b><i>in situ</i></b>HybridizationSemantic proximity Read ↗

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast CancerSemantic proximity Read ↗

Chromogenic <i>in situ</i> hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic <i>in situ</i> hybridization with immunohistochemistry and fluorescence <i>in situ</i> hybridizationSemantic proximity Read ↗

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.